Esperion Therapeutics (ESPR) Downgraded by BidaskClub
Esperion Therapeutics (NASDAQ:ESPR) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
A number of other brokerages have also issued reports on ESPR. Cowen set a $82.00 target price on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Friday, October 26th. ValuEngine raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 1st. Zacks Investment Research raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research note on Tuesday, July 31st. Stifel Nicolaus started coverage on shares of Esperion Therapeutics in a research note on Friday, September 14th. They issued a “buy” rating and a $89.00 price objective for the company. Finally, BTIG Research started coverage on shares of Esperion Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $82.00 price objective for the company. Two analysts have rated the stock with a sell rating, three have issued a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. Esperion Therapeutics currently has a consensus rating of “Buy” and an average price target of $75.96.
Shares of ESPR traded down $0.24 during trading hours on Tuesday, reaching $50.03. 586,200 shares of the company traded hands, compared to its average volume of 866,309. The firm has a market capitalization of $1.46 billion, a P/E ratio of -7.17 and a beta of 2.20. Esperion Therapeutics has a 12-month low of $33.06 and a 12-month high of $82.68.
In related news, Director Roger S. Newton sold 17,700 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $51.05, for a total value of $903,585.00. Following the completion of the sale, the director now directly owns 615,726 shares of the company’s stock, valued at $31,432,812.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Boxer Capital, Llc sold 100,000 shares of the company’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $56.38, for a total transaction of $5,638,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 177,327 shares of company stock valued at $9,732,065. 14.50% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $250,000. Opera Trading Capital purchased a new stake in shares of Esperion Therapeutics during the third quarter valued at about $173,000. Legal & General Group Plc lifted its position in shares of Esperion Therapeutics by 53.9% during the first quarter. Legal & General Group Plc now owns 6,751 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 2,363 shares during the last quarter. Creative Planning lifted its position in shares of Esperion Therapeutics by 42.0% during the third quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 2,236 shares during the last quarter. Finally, Keybank National Association OH lifted its position in shares of Esperion Therapeutics by 97.7% during the second quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 3,787 shares during the last quarter.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.